Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the research, development, and commercialization of innovative therapies targeting major liver diseases. Its primary focus is on nonalcoholic steatohepatitis (NASH), an advanced form of nonalcoholic fatty liver disease that represents a significant and growing health concern globally. The company has distinguished itself in the biotechnology and medical research sector by developing Rezdiffra, the first approved oral therapy specifically for NASH with moderate to advanced liver fibrosis. Rezdiffra is a liver-directed thyroid hormone receptor β (THR-β) agonist, shown in clinical trials to improve or stabilize liver fibrosis and resolve NASH when used alongside diet and exercise. Madrigal Pharmaceuticals is recognized for its robust growth prospects, driven by ongoing clinical research and a strong financial position that supports continued investment in novel therapeutics. The company plays a pivotal role in addressing unmet medical needs in hepatology, with its work impacting both the biotechnology sector and the broader healthcare market through improved outcomes for patients at risk of advanced liver disease and related complications.